Creagen Inc.

Creagen Inc., a minority-owned, SBA 8(a) certified small disadvantaged business headquartered in Woburn, Massachusetts, supplies custom chemical synthesis and antibody-conjugated drug development services to federal health and defense research agencies as a prime contractor exclusively (100% of recent awards). The company manufactures specialized small molecules, bioactive compound libraries, and preclinical drug candidates for infectious disease countermeasure research, operating under primary NAICS codes 541714 (Research and Development in the Physical, Engineering, and Life Sciences), 621511 (Medical Laboratories), and 325414 (Biological Product Manufacturing).

Creagen's customer base concentrates heavily on health research agencies within the Department of Health and Human Services. The National Institute of Allergy and Infectious Diseases (NIAID) anchors the footprint with three awards carrying $107.3 million combined potential value — representing 97% of Creagen's total award value. The Defense Health Agency places three additional awards worth $2.5 million combined, primarily for small molecule synthesis supporting the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Child Health and Human Development, the National Institute on Aging, and the National Center for Advancing Translational Sciences round out an active set of nine distinct customer agencies, though their combined contribution totals less than $300 thousand. The two value rankings diverge sharply: NIAID dominates both volume and dollars by an overwhelming margin, while smaller NIH institutes and CDC place lower-dollar purchase orders.

Creagen holds a $2.4 million single-award indefinite-delivery contract with the Defense Health Agency running through September 2027 for small molecule synthesis supporting USAMRIID's drug discovery programs. Two delivery orders placed under this vehicle in 2022 and 2023 account for $105 thousand of combined value. The vendor's most significant holding is a large NIAID IDIQ not yet detailed in the visible award set but referenced in purchase order summaries as worth $107.3 million and earmarked for HIV, hepatitis, and tuberculosis drug development. Recent named work includes a $94.4 thousand purchase order from the National Institute of Child Health and Human Development (September 2025) for chemical compound synthesis, a $66 thousand order from the National Institute on Aging (August 2024) for custom antibody-conjugated drug services, and an $80 thousand purchase order from the National Institute of Diabetes and Digestive and Kidney Diseases (July 2023) for bioactive molecule library acquisition. A $56 thousand purchase order from NIDDK awarded in August 2026 represents the most recent activity.

Award volume has declined across the five-year window — three awards in 2022 tapering to one each year in 2024, 2025, and 2026 — with only one award (combined potential value $56 thousand) facing ultimate completion within the next twenty-four months and presenting recompete exposure. Creagen operates solely as a prime contractor with no visible subcontract footprint. Set-aside posture splits between 8(a) small-business set-asides on smaller purchase orders and full-and-open competitive awards on larger IDIQs and delivery orders, indicating flexibility in positioning across customer procurement vehicle types.

CreaGen Inc. provides contract research services in organic synthesis, medicinal chemistry, lead optimization, small molecules, chemical library synthesis, conjugation chemistry, and antibody drug conjugation chemistry, analytical and bio-analytical chemistry.

We have more than 100 years of combined experience in working with over 48 biotech and pharmaceutical companies and federal institutes.

Our 22,000 sq ft facility has a full suite of infrastructure for synthesis, purification and characterization combined with a highly qualified team of chemists putting us in a strong position to deliver unparalleled drug discovery services to biotech, pharmaceutical companies and Federal research laboratories.